1. Home
  2. DPRO vs ACIU Comparison

DPRO vs ACIU Comparison

Compare DPRO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Draganfly Inc.

DPRO

Draganfly Inc.

HOLD

Current Price

$7.86

Market Cap

230.7M

Sector

Industrials

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.35

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DPRO
ACIU
Founded
1998
2003
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.7M
213.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
DPRO
ACIU
Price
$7.86
$3.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$15.67
$10.00
AVG Volume (30 Days)
2.5M
418.4K
Earning Date
11-12-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,335,758.00
$5,482,957.00
Revenue This Year
$50.81
N/A
Revenue Next Year
$149.77
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
26.74
N/A
52 Week Low
$1.63
$1.43
52 Week High
$14.40
$4.00

Technical Indicators

Market Signals
Indicator
DPRO
ACIU
Relative Strength Index (RSI) 43.67 48.39
Support Level $7.87 $3.24
Resistance Level $8.70 $3.90
Average True Range (ATR) 1.05 0.25
MACD -0.20 -0.03
Stochastic Oscillator 2.44 16.67

Price Performance

Historical Comparison
DPRO
ACIU

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: